Seamless Therapeutics

Seamless Therapeutics develops a gene-editing platform based on programmable recombinase technology, enabling large, precise DNA deletions and insertions anywhere in the human genome without introducing additional mutations. The company's approach uses programmable precision designer recombinases that can be reprogrammed to specific target sites, offering a seamless approach to treating severe genetic diseases by correcting the genetic cause rather than managing symptoms. Unlike CRISPR and other gene-editing technologies, Seamless's recombinase technology performs large edits with unparalleled precision and efficiency, expanding the therapeutic potential of gene editing across a broad spectrum of indications. The company has published foundational research in Nature Biotechnology, Genome Biology, and Nucleic Acids Research, demonstrating its ability to reprogram large serine recombinases to specific target sites. Seamless has established a global research collaboration with Eli Lilly to develop programmable recombinase-based therapeutics for hearing loss. The company's leadership team brings experience from Homology Medicines, Shire Pharmaceuticals, Pfizer, and Biogen, with the technology originating from research at the Max Planck Institute and Dresden University of Technology. Founded in 2022 and headquartered in Dresden, Germany with US operations in Lexington, Massachusetts, Seamless Therapeutics has raised $12.5M in seed funding from investors including Wellington Partners Venture Capital, Forbion, and GO-Bio.